27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic…
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence…
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…
Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine…
LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division…
LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results…
London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm,…
25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have…
Move brings AstraZeneca’s small molecule and MedImmune’s biologics research and development together at purpose-built facility on Cambridge Biomedical Campus 21-6-2013…